search button

The modifier subunit of glutamate cysteine ligase (GCLM) is a molecular target for amelioration of cisplatin resistance in lung cancer

  • Authors:
    • Yoshimasa Inoue
    • Masashi Tomisawa
    • Hitoshi Yamazaki
    • Yoshiyuki Abe
    • Hiroshi Suemizu
    • Hideo Tsukamoto
    • Yasushi Tomii
    • Masafumi Kawamura
    • Hiroshi Kijima
    • Hiroyuki Hatanaka
    • Yoshito Ueyama
    • Masato Nakamura
    • Koichi Kobayashi

  • View Affiliations

  • Published online on: November 1, 2003     https://doi.org/10.3892/ijo.23.5.1333
  • Pages: 1333-1339
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

It is unclear whether a subunit of glutamate cysteine ligase [a modifier subunit (GCLM) and a catalytic subunit (GCLC)] is an effective target for ameliorating cisplatin (CDDP)-resistance. We inhibited each subunit of GCL mRNA using a specific ribozyme (M-Rz and C-Rz) in the pulmonary adenocarcinoma cell line A549. GCL activity was suppressed by the ribozyme. CDDP-resistance was more effectively ameliorated when GCLM rather than GCLC was inhibited. GCLM is a potentially more effective pharmacologic target for ameliorating CDDP-resistance in non-small cell lung cancer than GCLC.

Related Articles

Journal Cover

November 2003
Volume 23 Issue 5

Print ISSN: 1019-6439
Online ISSN:1791-2423

Sign up for eToc alerts

Recommend to Library

  • Journal Metrics
  • Impact Factor: 4.5
  • Ranked Oncology
    (total number of cites)
  • CiteScore: 9.6
  • CiteScore Rank: Q1: #66/404 Oncology
  • Source Normalized Impact per Paper (SNIP): 0.88
  • SCImago Journal Rank (SJR): 1.099
International Symposium on Molecular Medicine Conference Banner
The Cancer Story
World Congress on Advances in Oncology and International Symposium on Molecular Medicine Conference Banner
World Academy Of Sciences Banner
Heyday Road Banner

0

Copy and paste a formatted citation
x
Spandidos Publications style
Inoue Y, Tomisawa M, Yamazaki H, Abe Y, Suemizu H, Tsukamoto H, Tomii Y, Kawamura M, Kijima H, Hatanaka H, Hatanaka H, et al: The modifier subunit of glutamate cysteine ligase (GCLM) is a molecular target for amelioration of cisplatin resistance in lung cancer. Int J Oncol 23: 1333-1339, 2003.
APA
Inoue, Y., Tomisawa, M., Yamazaki, H., Abe, Y., Suemizu, H., Tsukamoto, H. ... Kobayashi, K. (2003). The modifier subunit of glutamate cysteine ligase (GCLM) is a molecular target for amelioration of cisplatin resistance in lung cancer. International Journal of Oncology, 23, 1333-1339. https://doi.org/10.3892/ijo.23.5.1333
MLA
Inoue, Y., Tomisawa, M., Yamazaki, H., Abe, Y., Suemizu, H., Tsukamoto, H., Tomii, Y., Kawamura, M., Kijima, H., Hatanaka, H., Ueyama, Y., Nakamura, M., Kobayashi, K."The modifier subunit of glutamate cysteine ligase (GCLM) is a molecular target for amelioration of cisplatin resistance in lung cancer". International Journal of Oncology 23.5 (2003): 1333-1339.
Chicago
Inoue, Y., Tomisawa, M., Yamazaki, H., Abe, Y., Suemizu, H., Tsukamoto, H., Tomii, Y., Kawamura, M., Kijima, H., Hatanaka, H., Ueyama, Y., Nakamura, M., Kobayashi, K."The modifier subunit of glutamate cysteine ligase (GCLM) is a molecular target for amelioration of cisplatin resistance in lung cancer". International Journal of Oncology 23, no. 5 (2003): 1333-1339. https://doi.org/10.3892/ijo.23.5.1333